Toxicological Review of Phenol

Total Page:16

File Type:pdf, Size:1020Kb

Toxicological Review of Phenol EPA/635/R-02/006 TOXICOLOGICAL REVIEW OF Phenol (CAS No. 108-95-2) In Support of Summary Information on the Integrated Risk Information System (IRIS) September 2002 U.S. Environmental Protection Agency Washington D.C. DISCLAIMER Mention of trade names or commercial products does not constitute endorsement or recommendation for use. Note: This document may undergo revisions in the future. The most up-to-date version will be made available electronically via the IRIS Home Page at http://www.epa.gov/iris. CONTENTS - TOXICOLOGICAL REVIEW FOR PHENOL (CAS No. 108-95-2) Foreword................................................................... vi Authors, Contributors and Reviewers.......................................... vii 1. INTRODUCTION ......................................................1 2. CHEMICAL AND PHYSICAL INFORMATION RELEVANT TO ASSESSMENTS........................................................2 3. TOXICOKINETICS RELEVANT TO ASSESSMENTS ......................5 3.1 Absorption ......................................................5 3.2 Distribution.....................................................10 3.3 Metabolism.....................................................12 3.4 Excretion .......................................................23 4. HAZARD IDENTIFICATION ...........................................24 4.1 Studies in Humans - Epidemiology, Case Reports, Clinical Controls .....25 4.1.1 Oral .....................................................25 4.1.2 Inhalation ................................................27 4.2 Pre-chronic, Chronic Studies and Cancer Bioassays in Laboratory Animals ...............................................................32 4.2.1 Oral .....................................................32 4.2.2 Inhalation ................................................52 4.2.3 Dermal ...................................................60 4.3 Reproductive/Developmental Studies ...............................61 4.4 Other Studies ...................................................72 4.4.1 Initiation/Promotion Studies, Other Short-term Tumorigenicity Assays, and Cancer Mechanism Studies .......................72 4.4.2 Genotoxicity ..............................................75 4.4.3 Neurological Effects ........................................83 4.4.4 Immunotoxicity ...........................................84 4.4.5 Other Studies .............................................85 4.5 Synthesis and Evaluation of Major Noncancer Effects and Mode of Action ...............................................................86 4.6 Weight of Evidence Evaluation and Cancer Characterization - Synthesis of Human, Laboratory Animal and Other Supporting Evidence, Conclusions about Human Carcinogenicity, and Likely Mode of Action .............92 4.7 Susceptible Populations...........................................95 4.7.1 Possible Childhood Susceptibility .............................95 iii 4.7.2 Possible Gender Differences .................................96 5. DOSE RESPONSE ASSESSMENTS......................................96 5.1 Oral Reference Dose (RfD) .......................................97 5.1.1 Choice of Principal Study and Critical Effect ..................97 5.1.2 Method of Analysis - Benchmark dose .......................100 5.1.3 RfD Derivation ...........................................100 5.2 Inhalation Reference Concentration (RfC) .........................102 5.2.1 Choice of Principal Study and Critical Effect .................102 5.2.2 Methods of Analysis ......................................103 5.3 Cancer Assessment ............................................103 6. MAJOR CONCLUSIONS IN CHARACTERIZATION OF HAZARD AND DOSE- RESPONSE .........................................................104 6.1 Human Hazard Potential ........................................104 6.1.1 Oral Noncancer ..........................................104 6.1.2 Inhalation Noncancer .....................................106 6.1.3 Cancer ..................................................107 6.2 Dose-response..................................................107 7.0 REFERENCES.......................................................111 Appendix A. Summary of External Peer Review Comments and Disposition. 124 Appendix B. Benchmark Dose Modeling Results. 129 Appendix C. Benchmark Dose Modeling Output. 133 iv List of Tables and Figures Table 1. Physical Properties and Chemical Identity of Phenol .......................4 Table 2. Summary of Oral Toxicity Studies......................................34 Table 3. Total Activity Counts in Rats Provided Phenol in Drinking Water (ClinTrials BioResearch, 1998) ...........................................41 Table 4. Individual Data on Dehydration and Week 4 Motor Activity in Rats Provided Phenol in Drinking Water (ClinTrials BioResearch, 1998) ..........................................43 Table 5. Effects of Phenol Exposure on Spleen Cellularity and Selected Blood Parameters in Mice and Rats ...........................47 Table 6. Effects of Phenol Exposure on Spleen Cellularity and Selected Blood Parameters in Mice and Rats ......................................................49 Table 7. Summary of Inhalation Toxicity Studies.................................54 Table 8. Selected Results of Two-Generation Drinking Water Study (Ryan et al., 2001; IIT Research Institute, 1999) ............................63 Table 9. Key Results in Argus Research Laboratories, (1997) Rat Developmental Toxicity Study................................................................67 Table 10. Key Results from Developmental Toxicity Study in Rats Administered Phenol by Gavage (NTP, 1983a) ..............................69 Table 11. Summary of Genotoxicity Studies .....................................77 Figure 1. Metabolism of Phenol................................................13 Figure 2. Plot of severity with dose for drinking water or gavage ....................90 v FOREWORD The purpose of this Toxicological Review is to provide scientific support and rationale for the hazard identification and dose-response assessment in IRIS pertaining to chronic exposure to phenol. It is not intended to be a comprehensive treatise on the chemical or toxicological nature of phenol. In Section 6, EPA has characterized its overall confidence in the quantitative and qualitative aspects of hazard and dose-response. Matters considered in this characterization include knowledge gaps, uncertainties, quality of data, and scientific controversies. This characterization is presented in an effort to make apparent the limitations of the assessment and to aid and guide the risk assessor in the ensuing steps of the risk assessment process. For other general information about this assessment or other questions relating to IRIS, the reader is referred to EPA’s IRIS Hotline at 301-345-2870. vi AUTHORS, CONTRIBUTORS, AND REVIEWERS Chemical Manager/Author Monica A. Barron Office of Solid Waste U.S. Environmental Protection Agency Washington, DC Contract Authors Lynne Haber Toxicology Excellence for Risk Assessment Cincinnati, OH Andrew Maier Toxicology Excellence for Risk Assessment Cincinnati, OH Jay Zhao Toxicology Excellence for Risk Assessment Cincinnati, OH Michael Dourson Toxicology Excellence for Risk Assessment Cincinnati, OH Reviewers This document and summary information on IRIS have received peer review by both EPA scientists and independent scientists external to EPA. Subsequent to external review and incorporation of comments, this assessment underwent an Agency-wide review process whereby the IRIS Program Manager achieved a consensus approval among the Office of Research and Development; Office of Air and Radiation; Office of Prevention, Pesticides, and Toxic Substances; Office of Solid Waste and Emergency Response (OSWER) of Water; Office of Policy, Economics, and Innovation; Office of Children’s Health Protection; Office of Environmental Information; and the Regional Offices. Internal EPA Reviewers Dorothy Canter OSWER vii Nancy Chiu Office of Water, Health and Ecological Criteria Division (HECD) Annie Jarabek National Center for Environmental Assessment Edward Ohanian Office of Water/HECD Diana Wong Office of Water/HECD Robert MacPhail (reviewed portions) National Health and Environmental Effects Research Laboratory Selene Chou Agency for Toxic Substances Disease Registry External Peer Reviewers Rolf Hartung University of Michigan Michele Medinsky ToxCon Anthony Scialli Department of Obstetrics and Gynecology Georgetown University Medical Center Summaries of the external peer reviewers’ comments and the disposition of their recommendations are presented in Appendix A. viii 1. INTRODUCTION This document presents background and justification for the hazard and dose-response assessment summaries in U.S. Environmental Protection Agency’s (EPA’s) Integrated Risk Information System (IRIS). IRIS summaries may include an oral reference dose (RfD), an inhalation reference concentration (RfC), and a carcinogenicity assessment. The RfD and RfC provide quantitative information for noncancer dose-response assessments. The RfD is based on the assumption that thresholds exist for certain toxic effects such as cellular necrosis but may not exist for other toxic effects such as some carcinogenic responses. It is expressed in units of milligrams per kilogram per day (mg/kg-day). In general, the RfD is an estimate (with uncertainty spanning perhaps an order of magnitude) of a daily exposure to the human population (including sensitive subgroups)
Recommended publications
  • Plant Phenolics: Bioavailability As a Key Determinant of Their Potential Health-Promoting Applications
    antioxidants Review Plant Phenolics: Bioavailability as a Key Determinant of Their Potential Health-Promoting Applications Patricia Cosme , Ana B. Rodríguez, Javier Espino * and María Garrido * Neuroimmunophysiology and Chrononutrition Research Group, Department of Physiology, Faculty of Science, University of Extremadura, 06006 Badajoz, Spain; [email protected] (P.C.); [email protected] (A.B.R.) * Correspondence: [email protected] (J.E.); [email protected] (M.G.); Tel.: +34-92-428-9796 (J.E. & M.G.) Received: 22 October 2020; Accepted: 7 December 2020; Published: 12 December 2020 Abstract: Phenolic compounds are secondary metabolites widely spread throughout the plant kingdom that can be categorized as flavonoids and non-flavonoids. Interest in phenolic compounds has dramatically increased during the last decade due to their biological effects and promising therapeutic applications. In this review, we discuss the importance of phenolic compounds’ bioavailability to accomplish their physiological functions, and highlight main factors affecting such parameter throughout metabolism of phenolics, from absorption to excretion. Besides, we give an updated overview of the health benefits of phenolic compounds, which are mainly linked to both their direct (e.g., free-radical scavenging ability) and indirect (e.g., by stimulating activity of antioxidant enzymes) antioxidant properties. Such antioxidant actions reportedly help them to prevent chronic and oxidative stress-related disorders such as cancer, cardiovascular and neurodegenerative diseases, among others. Last, we comment on development of cutting-edge delivery systems intended to improve bioavailability and enhance stability of phenolic compounds in the human body. Keywords: antioxidant activity; bioavailability; flavonoids; health benefits; phenolic compounds 1. Introduction Phenolic compounds are secondary metabolites widely spread throughout the plant kingdom with around 8000 different phenolic structures [1].
    [Show full text]
  • Metabolism of Non-Growing Cells and Their Application in Biotransformation
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 17 July 2020 doi:10.20944/preprints202007.0402.v1 Metabolism of non-growing cells and their application in biotransformation Wenfa Ng Department of Chemical and Biomolecular Engineering, National University of Singapore, Email: [email protected] Abstract Growing cells is the typical mode of operation in many aspects of biotechnology and metabolic engineering. This comes about due to cell growth processes creating a driving force that pull metabolic flux along different metabolic pathways, that indirectly help move substrate to product. But, there is an alternative mode of operation that uses resting (non-growing) cells to achieve similar or even higher productivities. In general, resting cells are provided with carbon substrates for biocatalytic reactions but starved of nitrogen or phosphorus. Such resting cells have been usefully employed in many forms of biocatalysis and biotransformation, with or without cofactor regeneration. However, much remains unknown about the transcriptome and metabolome of resting cells in biotransformation settings. This short writeup provides the backdrop of resting cells in biocatalysis, documents their use in biotransformation with application examples, and identifies research gaps that could be filled with contemporary RNA- seq and mass spectrometry proteomics technology. Overall, utility of resting cells in biocatalysis and the extant knowledge gap in their fundamental physiology are highlighted in this resource. Keywords: resting cells, biocatalysis, cofactor regeneration, transcriptome, biotransformations, Subject areas: biochemistry, biotechnology, bioinformatics, systems biology, molecular biology, Non-growing (resting) cells in biotransformation Biotransformations sought the use of enzymes and whole cells for the conversion of substrates into desired products. Typically, whole cell biocatalysts are used given problems with instability and purification of pure enzymes.
    [Show full text]
  • Smitha MS, Singh S, Singh R. Microbial Biotransformation: a Process for Chemical Alterations
    Journal of Bacteriology & Mycology: Open Access Mini Review Open Access Microbial biotransformation: a process for chemical alterations Abstract Volume 4 Issue 2 - 2017 Biotransformation is a process by which organic compounds are transformed from one Smitha MS, Singh S, Singh R form to another to reduce the persistence and toxicity of the chemical compounds. This Amity University Uttar Pradesh, India process is aided by major range of microorganisms and their products such as bacteria, fungi and enzymes. Biotransformations can also be used to synthesize compounds Correspondence: Singh R, Additional Director, Amity Institute or materials, if synthetic approaches are challenging. Natural transformation process of Microbial Biotechnology, Amity University, Sector 125, Noida, is slow, nonspecific and less productive. Microbial biotransformations or microbial UP, India, Tel +911204392900, Email [email protected] biotechnology are gaining importance and extensively utilized to generate metabolites in bulk amounts with more specificity. This review was conceived to assess the Received: November 21, 2016 | Published: February 21, 2017 impact of microbial biotransformation of steroids, antibiotics, various pollutants and xenobiotic compounds. Keywords: microbial biotransformation; bioconversion; metabolism; steroid; bacteria, fungi Introduction the metabolism of compounds using animal models.9 The microbial biotransformation phenomenon is then commonly employed Biotransformations are structural modifications in a chemical in comparing metabolic
    [Show full text]
  • Human Health Toxicity Values for Perfluorobutane Sulfonic Acid (CASRN 375-73-5) and Related Compound Potassium Perfluorobutane Sulfonate (CASRN 29420 49 3)
    EPA-823-R-18-307 Public Comment Draft Human Health Toxicity Values for Perfluorobutane Sulfonic Acid (CASRN 375-73-5) and Related Compound Potassium Perfluorobutane Sulfonate (CASRN 29420-49-3) This document is a Public Comment draft. It has not been formally released by the U.S. Environmental Protection Agency and should not at this stage be construed to represent Agency policy. This information is distributed solely for the purpose of public review. This document is a draft for review purposes only and does not constitute Agency policy. DRAFT FOR PUBLIC COMMENT – DO NOT CITE OR QUOTE NOVEMBER 2018 Human Health Toxicity Values for Perfluorobutane Sulfonic Acid (CASRN 375-73-5) and Related Compound Potassium Perfluorobutane Sulfonate (CASRN 29420 49 3) Prepared by: U.S. Environmental Protection Agency Office of Research and Development (8101R) National Center for Environmental Assessment Washington, DC 20460 EPA Document Number: 823-R-18-307 NOVEMBER 2018 This document is a draft for review purposes only and does not constitute Agency policy. DRAFT FOR PUBLIC COMMENT – DO NOT CITE OR QUOTE NOVEMBER 2018 Disclaimer This document is a public comment draft for review purposes only. This information is distributed solely for the purpose of public comment. It has not been formally disseminated by EPA. It does not represent and should not be construed to represent any Agency determination or policy. Mention of trade names or commercial products does not constitute endorsement or recommendation for use. i This document is a draft for review purposes only and does not constitute Agency policy. DRAFT FOR PUBLIC COMMENT – DO NOT CITE OR QUOTE NOVEMBER 2018 Authors, Contributors, and Reviewers CHEMICAL MANAGERS Jason C.
    [Show full text]
  • Biosynthesis of New Alpha-Bisabolol Derivatives Through a Synthetic Biology Approach Arthur Sarrade-Loucheur
    Biosynthesis of new alpha-bisabolol derivatives through a synthetic biology approach Arthur Sarrade-Loucheur To cite this version: Arthur Sarrade-Loucheur. Biosynthesis of new alpha-bisabolol derivatives through a synthetic biology approach. Biochemistry, Molecular Biology. INSA de Toulouse, 2020. English. NNT : 2020ISAT0003. tel-02976811 HAL Id: tel-02976811 https://tel.archives-ouvertes.fr/tel-02976811 Submitted on 23 Oct 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE En vue de l’obtention du DOCTORAT DE L’UNIVERSITÉ DE TOULOUSE Délivré par l'Institut National des Sciences Appliquées de Toulouse Présentée et soutenue par Arthur SARRADE-LOUCHEUR Le 30 juin 2020 Biosynthèse de nouveaux dérivés de l'α-bisabolol par une approche de biologie synthèse Ecole doctorale : SEVAB - Sciences Ecologiques, Vétérinaires, Agronomiques et Bioingenieries Spécialité : Ingénieries microbienne et enzymatique Unité de recherche : TBI - Toulouse Biotechnology Institute, Bio & Chemical Engineering Thèse dirigée par Gilles TRUAN et Magali REMAUD-SIMEON Jury
    [Show full text]
  • The Sensitivity of Young Animals to Benzo[A]Pyrene-Induced Genotoxic Stress
    The sensitivity of young animals to benzo[a]pyrene-induced genotoxic stress RIVM report 340701002/2013 M. Luijten et al. National Institute for Public Health and the Environment P.O. Box 1 | 3720 BA Bilthoven www.rivm.com The sensitivity of young animals to benzo[a]pyrene-induced genotoxic stress RIVM Report 340701002/2013 RIVM Report 340701002 Colophon © RIVM 2013 Parts of this publication may be reproduced, provided acknowledgement is given to the 'National Institute for Public Health and the Environment', along with the title and year of publication. Mirjam Luijten Lya G. Hernández Edwin P. Zwart Peter M. Bos Harry van Steeg Jan van Benthem Contact: Mirjam Luijten Center for Health Protection [email protected] This investigation has been performed by order and for the account of the Netherlands Food and Consumer Product Safety Authority, within the framework of project V/340701 'CMRI-stoffen in het jonge kind'. RIVM Report 340701002 Abstract Young animals are more sensitive than adult animals to benzo[a]pyrene-induced genotoxic stress Experimental animals are more sensitive at a young age to the adverse effects induced upon benzo[a]pyrene exposure compared to adult animals. In research performed at the RIVM, higher amounts of DNA damage were observed when benzo[a]pyrene was given to experimental animals at a young age. Usually, potential adverse human health effects of environmental chemicals are evaluated in toxicity studies using adult laboratory animals. Children and adults, however, may differ in sensitivity to these adverse effects. Benzo[a]pyrene is commonly found in grilled and broiled foods, tobacco smoke and automobile exhaust fumes.
    [Show full text]
  • Microbial Transformation of Xenobiotics for Environmental Bioremediation
    African Journal of Biotechnology Vol. 8 (22), pp. 6016-6027, 16 November, 2009 Available online at http://www.academicjournals.org/AJB ISSN 1684–5315 © 2009 Academic Journals Review Microbial transformation of xenobiotics for environmental bioremediation Shelly Sinha1, Pritam Chattopadhyay2, Ieshita Pan1, Sandipan Chatterjee1, Pompee Chanda1, 1 1 1 Debashis Bandyopadhyay , Kamala Das and Sukanta K. Sen * 1Microbiology Division, Department of Botany, Visva-Bharati, Santiniketan, 731 235, India. 2Plant Biotechnology Division, Department of Botany, Visva-Bharati, Santiniketan, 731 235, India. Accepted 4 September, 2009 The accumulation of recalcitrant xenobiotic compounds is due to continuous efflux from population and industrial inputs that have created a serious impact on the pristine nature of our environment. Apart from this, these compounds are mostly carcinogenic, posing health hazards which persist over a long period of time. Metabolic pathways and specific operon systems have been found in diverse but limited groups of microbes that are responsible for the transformation of xenobiotic compounds. Distinct catabolic genes are either present on mobile genetic elements, such as transposons and plasmids, or the chromosome itself that facilitates horizontal gene transfer and enhances the rapid microbial transformation of toxic xenobiotic compounds. Biotransformation of xenobiotic compounds in natural environment has been studied to understand the microbial ecology, physiology and evolution for their potential in bioremediation. Recent advance in the molecular techniques including DNA fingerprinting, microarrays and metagenomics is being used to augment the transformation of xenobiotic compounds. The present day understandings of aerobic, anaerobic and reductive biotransformation by co-metabolic processes and an overview of latest developments in monitoring the catabolic genes of xenobiotic-degrading bacteria are discussed elaborately in this work.
    [Show full text]
  • Biotransformation of Hydroxychalcones As a Method of Obtaining Novel and Unpredictable Products Using Whole Cells of Bacteria
    catalysts Article Biotransformation of Hydroxychalcones as a Method of Obtaining Novel and Unpredictable Products Using Whole Cells of Bacteria Joanna Kozłowska 1,* , Bartłomiej Potaniec 1,2 and Mirosław Anioł 1 1 Department of Chemistry, Faculty of Biotechnology and Food Science, Wrocław University of Environmental and Life Sciences, Norwida 25, 50-375 Wrocław, Poland; [email protected] (B.P.); [email protected] (M.A.) 2 Łukasiewicz Research Network—PORT Polish Center for Technology Development, Stabłowicka 147, 54-066 Wrocław, Poland * Correspondence: [email protected] Received: 27 September 2020; Accepted: 8 October 2020; Published: 12 October 2020 Abstract: The aim of our study was the evaluation of the biotransformation capacity of hydroxychalcones—2-hydroxy-40-methylchalcone (1) and 4-hydroxy-40-methylchalcone (4) using two strains of aerobic bacteria. The microbial reduction of the α,β-unsaturated bond of 2-hydroxy-40- methylchalcone (1) in Gordonia sp. DSM 44456 and Rhodococcus sp. DSM 364 cultures resulted in isolation the 2-hydroxy-40-methyldihydrochalcone (2) as a main product with yields of up to 35%. Additionally, both bacterial strains transformed compound 1 to the second, unexpected product of reduction and simultaneous hydroxylation at C-4 position—2,4-dihydroxy-40-methyldihydrochalcone (3) (isolated yields 12.7–16.4%). During biotransformation of 4-hydroxy-40-methylchalcone (4) we observed the formation of three products: reduction of C=C bond—4-hydroxy-40-methyldihydrochalcone (5), reduction of C=C bond and carbonyl group—3-(4-hydroxyphenyl)-1-(4-methylphenyl)propan-1-ol (6) and also unpredictable 3-(4-hydroxyphenyl)-1,5-di-(4-methylphenyl)pentane-1,5-dione (7).
    [Show full text]
  • Biotransformation of Vincamine Using Microbial Cultures
    IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS) e-ISSN: 2278-3008, p-ISSN:2319-7676. Volume 9, Issue 3 Ver. I (May -Jun. 2014), PP 71-78 www.iosrjournals.org Biotransformation of Vincamine using Microbial cultures Venisetty RK, Keshetty S and Ciddi Veeresham* University College of Pharmaceutical Sciences, Kakatiya University, Warangal AP 506009, India Abstract: Microbial transformation is a complementary tool in the investigation of drug metabolism. In the present investigation, biotransformation of vincamine was studied using microbial cultures. Bacterial, fungal, and yeast cultures were employed to elucidate the metabolism of vincamine. The results indicate that a number of microorganisms metabolized vincamine to various levels to yield three major metabolites, which were identified by HPLC-DAD and LC-MS-MS analyses. HPLC analysis of the extracts of the cultures showed that 16 out of 39 cultures were able to metabolize vincamine to produce one or more metabolites and the biotransformed products are more polar than the substrate vincamine. Out of 16 cultures maximum biotransformation of vincamine was observed with the cultures of Absidia coerulea MTCC 1335. The major metabolite was hydroxylated metabolite of vincamine, while the other metabolites were produced by dihydroxylation and methyl hydroxylation which are not seen in mammalian metabolism. The results will support the formation of new metabolites and more polar metabolites which have significance in the improvement of pharmacokinetic parameters of vincamine derivatives. Keywords: Biotransformation, Microbial Cell Cultures, Vincamine, Metabolites, HPLC, LC-MS-MS I. Introduction An important factor in the evaluation of safety and efficacy of any drug is the knowledge of how it is metabolized.
    [Show full text]
  • TCEQ Guidelines to Develop 24-Hour Inhalation Reference Values
    White Paper Final, June 16, 2014 TCEQ Guidelines to Develop 24-Hour Inhalation Reference Values Office of the Executive Director ___________________________________________________________ TEXAS COMMISSION ON ENVIRONMENTAL QUALITY 24-Hour Inhalation Reference Values Page i Document Description and Intended Use This document provides guidelines to develop chemical-specific 24-h reference values (ReVs). It is a supplement to the TCEQ Regulatory Guidance-442 (RG-442), TCEQ Guidelines to Develop Toxicity Factors. For chemicals evaluated in the TCEQ ambient air monitoring network, acute 1-h ReVs and chronic ReVs have generally been derived to evaluate 1-h measured concentrations of chemicals of interest or calculated annual average concentrations, respectively. These averaging times correspond to averaging times evaluated in air permitting. However, 24-h ambient air samples (e.g., 24-h canister samples collected every 3rd or 6th day) may be collected for special projects and also at permanent monitoring sites to calculate annual averages for comparison to chronic ReVs. A 24-h sample is an acute exposure duration significantly longer than 1-hr. Toxic effects induced by 24-h exposure may be governed by modes of action somewhat different than those influencing toxicity due to 1-h or chronic exposure. Therefore, it is not appropriate to use a short-term, 1-h ReV or long-term ReV to evaluate a 24-h ambient air sample. Thus, the development of a 24-h ReV would allow the TCEQ to fully evaluate 24-h air monitoring data for possible health concerns and could be used for risk communication purposes. In addition, this information is helpful to risk assessors for performing health effects reviews when 24-h air monitoring data exceed chronic ReVs.
    [Show full text]
  • NST110: Advanced Toxicology Lecture 4: Phase I Metabolism
    Absorption, Distribution, Metabolism and Excretion (ADME): NST110: Advanced Toxicology Lecture 4: Phase I Metabolism NST110, Toxicology Department of Nutritional Sciences and Toxicology University of California, Berkeley Biotransformation The elimination of xenobiotics often depends on their conversion to water-soluble chemicals through biotransformation, catalyzed by multiple enzymes primarily in the liver with contributions from other tissues. Biotransformation changes the properties of a xenobiotic usually from a lipophilic form (that favors absorption) to a hydrophilic form (favoring excretion in the urine or bile). The main evolutionary goal of biotransformation is to increase the rate of excretion of xenobiotics or drugs. Biotransformation can detoxify or bioactivate xenobiotics to more toxic forms that can cause tumorigenicity or other toxicity. Phase I and Phase II Biotransformation Reactions catalyzed by xenobiotic biotransforming enzymes are generally divided into two groups: Phase I and phase II. 1. Phase I reactions involve hydrolysis, reduction and oxidation, exposing or introducing a functional group (-OH, -NH2, -SH or –COOH) to increase reactivity and slightly increase hydrophilicity. O R1 - O S O sulfation O R2 OH Phase II Phase I R1 R2 R1 R2 - hydroxylation COO R1 O O glucuronidation OH R2 HO excretion OH O COO- HN H -NH2 R R1 R1 S N 1 Phase I Phase II COO O O oxidation glutathione R2 OH R2 R2 conjugation 2. Phase II reactions include glucuronidation, sulfation, acetylation, methylation, conjugation with glutathione, and conjugation with amino acids (glycine, taurine and glutamic acid) that strongly increase hydrophilicity. Phase I and II Biotransformation • With the exception of lipid storage sites and the MDR transporter system, organisms have little anatomical defense against lipid soluble toxins.
    [Show full text]
  • Pharmacokinetics and Toxicokinetics
    Pharmacokinetics and Toxicokinetics Howard A. Greller, MD FACEP FACMT North Shore University Department of Emergency Medicine Division of Medical Toxicology WHAT WE’LL COVER TODAY • Pharmacokinetics/Toxicokinetics • Absorption • Distribution • Metabolism • Elimination • Pharmacodynamics/Toxicodynamics • Xenobiotic interactions • Pharmacogenomics/Toxicogenomics OVERVIEW Tissue Therapy Toxicity Absorption Elimination Dose Drug Excretion Liberation Metabolite Protein Biotransformation ABSORPTION •Process by which a xenobiotic enters body •Rate of absorption (ka) determined by: •Route of administration •Dosing form •Bioavailability ROUTE OF ABSORPTION •Affects rate and extent •IV, inhalation > IM, SQ, IN, PO> SQ, PR •Onset dependent on route ROUTE OF ABSORPTION Oral, onset approximately 20 minutes ROUTE OF ABSORPTION Smoking ~10 seconds, IV ~30 seconds DISSOLUTION DIFFUSION DISINTEGRATION EROSION OSMOTIC PUMPS ION EXCHANGE RESINS BIOAVAILABILITY •Amount reaches systemic circulation, unchanged •Extent of absorption •Predicts intensity of effect •First pass effects modify bioavailability FIRST PASS EFFECTS • Prevention of absorption • Decon / chelation (+/-) • P-glycoprotein • Bezoars, mod preps • Pre-systemic metabolism • Hepatic, gastric mucosa, intestinal BB • Bacterial • Saturable in overdose FIRST PASS EXAMPLES • Gastric emptying time • Food, medications • Gastric ADH • Age, sex, H2 • “worst case” • High FP (“low bioavailability”) • Propranolol, cyclosporine, morphine, TCAs IONIZATION • Uncharged, non-polar cross membranes • pH + pKa (dissociation
    [Show full text]